spacer
home > news > detailed info
INDUSTRY NEWS AND PRESS RELEASES

Norwich Pharmaceuticals Announces Significant Business Growth

Norwich Clinical Services

Increased project volume, new clients propel revenues and expanded services

Norwich Pharmaceuticals, a provider of full-service contract development and manufacturing services for the pharmaceutical and biotech industry, announced today that the company has achieved significant business growth in first quarter, 2012 as compared to the same period in 2011. Key growth areas include volume of projects currently in development and commercial production, scope of projects expanded into multiple service categories, and total value of new business won.

"Norwich’s growth is a direct result of our ability to maintain high quality standards while providing expertise and flexibility for both product development and commercial manufacturing," said Terry Novak, president of Norwich. "During the past year, Norwich has expanded our capabilities to meet the market demands for smaller scale development services. Providing expertise in novel, solid dose formulations, we have been able to offer services to new clientele while increasing our repeat business rate with current customers."

New client awards in the first quarter accounted for 33% of all Norwich projects while repeat business in Q1, 2012 more than doubled as compared to the same period last year. The total value of new projects increased 25%. Several of the new projects will utilize Norwich services for potent compounds, low humidity, bead extrusion, tablet coating, formulation development, BA/BE studies, and global packaging and distribution.

About Norwich Pharmaceuticals

Norwich is a full-service contract development and manufacturing provider for Rx and OTC pharmaceuticals. Norwich applies more than 120 years of experience and an unparalleled compliance record to offer customers greater flexibility, resources and speed that result in a streamlined progression from product development to scale-up and commercial manufacturing through clinical services. Visit www.norwichpharma.com for more information.

phone +1 888 674 7979
email info@norwichpharma.com
web www.norwichpharma.com
email 6826 State Highway 12, Norwich, NY 13815, UNITED STATES
 
Print this page
Send to a friend
   
spacer
News and Press Releases

Samedan app – now available!

Samedan Ltd has launched a new app for iPhone and iPad, bringing together the digital editions of its six market-leading titles.
More info >>


White Papers

PROTEIN:PROTEIN INTERACTION ANALYSIS

IBA GmbH

Groth et al., 2007 and Jasencakova et al., 2010 Protein:protein-interactions (PPI) govern almost all important processes in living organisms. Thus, their rapid and accurate determination and investigation is a major challenge in life sciences. The extremely efficient and fast One-STrEP (Twin-Strep) system is suitable for the isolation of functional protein complexes and subsequent mass spectrometry analysis leads to the identification of protein complex components (Junttila et al., 2005) as it is shown in the following studies.
More info >>

Industry Events

Clinical Trials in CNS

11-12 November 2014, Marriott Regents Park Hotel, London, UK

SMi is delighted to announce its 13th annual Clinical Trials in CNS Conference. With an ever increasing average life expectancy, neurodegenerative diseases are becoming more prevalent in society.
More info >>

 
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement